BCLI
BRAINSTORM CELL THERAPEUTICS INC.
NASDAQ · Healthcare · Biotechnology · US
$0.90
−8.16%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.00
From 52W high−37.50%
Volume15203.00
Market cap$9.91M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$1.00
From 52W high
−37.50%
Volume
15203.00
Market cap
$9.91M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.2x
P/E (TTM)
—
RSI (14)
46.5
MomentumView details →
1D Return
−8.16%
YTD Return
+78.18%
SummaryUpdated Jun 1, 2026
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) is a biotechnology company founded in 2000 and incorporated in New York. Originally established as Golden Hand Resources Inc., the company changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 and went public in October 2003. The company specializes in developing autologous cellular therapies for neurodegenerative diseases, with its flagship product NurOwn currently in late-stage clinical trials for amyotrophic lateral sclerosis (ALS). Brainstorm has faced significant financial challenges in recent years, operating with minimal cash reserves while pursuing regulatory approval for its lead therapy.
Similar companies
Latest newsMore news →
BrainStorm Cell Therapeutics Inc. announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update on its NurOwn ALS program preparations for the Phase 3b ENDURANCE study.37d agoLunai Bioworks signed a definitive collaboration agreement with BrainStorm Therapeutics, with initial Parkinson's disease data readout targeted for the first half of 2027.47d ago